Gilead Presents New Data on Twice-Yearly Lenacapavir (Yeztugo®) for HIV Prevention at IAS 2025

Gilead Sciences announced new Phase 3 PURPOSE trial data for its recently FDA-approved, twice-yearly HIV PrEP drug, lenacapavir (Yeztugo®), demonstrating strong efficacy and tolerability across diverse populations, including pregnant/lactating women and adolescents, and compatibility with TB treatments. The data also revealed significant patient preference for the injectable over daily oral PrEP, reinforcing Yeztugo's market position as the first and only twice-yearly HIV prevention option. This clinical validation supports Gilead's ongoing global regulatory filings and strategic partnerships, solidifying its leadership in the HIV prevention landscape.

Analysis

Gilead Sciences has significantly de-risked the commercial outlook for its recently FDA-approved HIV prevention drug, Yeztugo (lenacapavir), with new Phase 3 PURPOSE trial data. The results, presented at IAS 2025, demonstrate strong efficacy and tolerability in previously underrepresented and high-risk populations, including pregnant/lactating women and adolescents, with zero new HIV infections reported among 184 participants in the pregnant cohort receiving Yeztugo. This intentional inclusion in trial design broadens the drug's potential market and provides a key differentiator. Critically, the data reveals a compelling patient preference for Yeztugo's twice-yearly injectable administration over daily oral medication, with over 75% of surveyed participants favoring the injectable, citing improved confidence in adherence (77%) and protection (69%). This addresses a primary challenge of oral PrEP and supports a strong adoption trajectory. The positive clinical profile underpins Gilead's global regulatory strategy, which includes an accelerated review timeline with the European Medicines Agency (EMA) and new filings in multiple countries. The strategic, non-profit partnership with The Global Fund further solidifies Gilead's market leadership and ESG credentials by expanding access to up to two million people in high-need regions.

Key Decisions for Investors

• The combination of recent FDA approval, robust efficacy data in expanded populations, and strong patient preference positions Yeztugo to become a new standard of care in HIV prevention, supporting a bullish outlook on its potential to capture significant market share from daily oral PrEP therapies.
• Investors should closely monitor near-term catalysts, particularly the regulatory decision from the EMA under its accelerated assessment timeline, as successful approvals in Europe and other key markets are critical for realizing the drug's global revenue potential.
• While the high market impact score and positive sentiment are justified, it is prudent to track the real-world adoption rates and adherence post-launch, as well as any emerging long-term safety data, which will be crucial for sustaining momentum against potential future competitors in the long-acting injectable space.
• Consider the strategic value of the no-profit partnership with The Global Fund, which enhances Gilead's ESG profile and builds long-term goodwill and market presence in emerging economies, potentially attracting capital from sustainability-focused funds.